H146
4-Hydroxymephenytoin
≥98% (HPLC)
Synonym(s):
(±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylhydantoin, (±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylimididazolidine-2,4-dione
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C12H14N2O3
CAS Number:
Molecular Weight:
234.25
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
solubility
DMSO: >5 mg/mL
SMILES string
CCC1(NC(=O)N(C)C1=O)c2ccc(O)cc2
InChI
1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)
InChI key
OQPLORUDZLXXPD-UHFFFAOYSA-N
General description
CYP2C19 metabolite of mephenytoin.
Application
Pharmacological activity investigating:
Analyte for electron-capture gas chromatography procedures
- The drug effects on metabolization
- In vitro cytochrome P450 activity in microsomes
Analyte for electron-capture gas chromatography procedures
Still not finding the right product?
Explore all of our products under 4-Hydroxymephenytoin
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M. Salsali, et al.,
Journal of Pharmacological and Toxicological Methods, 44, 461-465 (2001)
Sonja Krösser et al.
European journal of clinical pharmacology, 62(4), 277-284 (2006-03-10)
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate
A Adedoyin et al.
Clinical pharmacology and therapeutics, 64(1), 8-17 (1998-08-08)
Drug metabolism is influenced by liver disease because of the central role that the liver plays in metabolic activities in the body. However, it is still unclear how activities of specific drug-metabolizing enzymes are influenced by the presence and severity